Formulation and Evaluation of Immediate Release Tablet Dosage Form of Linagliptin and Metformin Hydrochloride
Abstract
The aim of the current study work was to formulate and assess a fixed dose mixture tablet of instant release oral solid dosage form comprising two anti-diabetic drugs (linagliptin and metformin hydrochloride) for managing of diabetes mellitus type 2.The innovator drug product (Jentadueto Tablet) was evaluated for the various evaluation parameters, which have been taken into consideration during the drug product development. Pre-formulation evaluation was accomplished to safeguard better parameters of formulated drug product. On the result of pre-formulation evaluation and innovator drug product characterization, the model drug product was recognized in various steps. The established formulation was augmented for different excipients. The instant release film covered tablet of linagliptin and metformin HCl was expressed and augmented at laboratory scale. The individual steps (procedures) were improved for the same and the scale-up contemplation have been engaged into account certify the product performance at pilot plant-up to commercial scale-up.
Keywords: anti-diabetic, linagliptin, metformin
Keywords:
anti-diabetic, linagliptin, metforminDOI
https://doi.org/10.22270/jddt.v11i3-S.4831References
Sicree R., Shaw J., Zimmet P. Prevalence and projections. In: Gan D (ed.). Diabetes Atlas International Diabetes Federation, 3rdedn. International Diabetes Federation, Brussels, Belgium, 2006; 16-104.
Clifford J. Bailey., Caroline D. Antidiabetic drugs, The British Journal of Cardiology, 2003; 10:128–36.
Halimi S., Schweizer A., Minic B., Foley J., Dejager S. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet, Vascular Health and Risk Management, 2008; 4(3):481–492.
Gohel N., Patel D.M., Patel K., Modi J. Formulation Development and Evaluation of Modified Release Tablet using a Fixed Dose Combination of Antidiabetic Agents, International Journal of Pharmaceutical Sciences Review and Research, 2017; 42(2):139-145.
Blonde L., Juan Z.T.S. Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus, Advances in Therapy, 2012; 29(1):1-13. DOI 10.1007/s12325-011-0094-1.
Khan M.D.P., Basha S.A.A., Mudabbir M.A.H. Formulation and Evaluation of Bilayer Matrix Tablets for Controlled Delivery of Metformin HCl and Vildagliptin, 2014; 6(2):6739-6756.
Kupsal K., Mudigonda S., Nyayapathi V.B.K.S., Neelala K., Hanumanth S.R. Metformin Combinatorial Therapy for Type 2 Diabetes Mellitus, Journal of Metabolic Syndrome, 2016; 5:210. doi: 10.4172 / 2167-0943.1000210.
Prajapati T.K. Development and Evaluation of Combination Formulation for the Immediate Delivery of Vildagliptin HCl and the Sustained Delivery of Metformin, International Journal of Current Advanced Research, 2018; 74:12097-12104.
Published
Abstract Display: 1739 
PDF Downloads: 3178 PDF Downloads: 364 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.